Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Targeted therapy with PI3K inhibitor boosts PFS in advanced breast cancer

Andre F et al. ESMO 2018, Abstract LBA3_PR.

Key clinical point: Alpelisib, selective for the alpha isoforms of the phosphatidylinositol 3-kinase, appears to have better tolerability than, and similar efficacy to, pan–phosphoinositide 3-kinase inhibitors.

Major finding: Median progression-free survival was 11 months with alpelisib/fulvestrant in patients with PIK3CA mutations, compared with 5.7 months for placebo/fulvestrant.

Study details: A randomized, phase 3 trial in 572 patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Disclosures: SOLAR-1 was sponsored by Novartis. Dr. André disclosed research grants from Novartis and others; Dr. Dent disclosed advisory board, honoraria, or travel support from Novartis and others; Dr. Harbeck disclosed honoraria for consulting and lecturing for Pfizer and others.

Read the article.

Citation:

Andre F et al. ESMO 2018, Abstract LBA3_PR.